119 results
Page 2 of 6
6-K
EX-99
4mhzsvjcwgkg27lg2o
12 Oct 23
BioLineRx Announces Closing of Exclusive License Agreement to Motixafortide
7:14am
6-K
EX-99
t2fn1m4mnol
28 Sep 23
BioLineRx Announces Encouraging Data from Pilot Phase of Phase 2 Combination
7:11am
6-K
EX-99
ke2j0x7
11 Sep 23
BioLineRx Announces FDA Approval of APHEXDA™ (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple
7:07am
6-K
EX-99
a93nnje9
30 Aug 23
BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate
7:15am
6-K
EX-99
6epcxb
30 Aug 23
BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate
7:15am
6-K
EX-99
2722 bg9k
30 Aug 23
BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate
7:15am
6-K
EX-1
4saoyj 5iz4pz
17 Jul 23
BioLineRx Announces Initiation of Randomized Phase 2 Clinical Trial in First Line Metastatic
7:10am
6-K
EX-99
1vwyyb
23 Jun 23
Notice of Annual General Meeting of Shareholders
4:16pm
6-K
EX-99
ptgs8u9d34 72b3fqx
24 May 23
BioLineRx Reports First Quarter 2023 Financial Results and Recent Corporate
7:06am
6-K
EX-99
9ek rtlkdungkp2o
24 May 23
BioLineRx Reports First Quarter 2023 Financial Results and Recent Corporate
7:06am
6-K
EX-99
a1xk0b0hnxjvpkb
15 Nov 22
BioLineRx Reports Third Quarter 2022 Financial Results and Recent Corporate
7:07am
6-K
EX-99
tct4zoic3grf 6fsi
27 Sep 22
BioLineRx Announces U.S. Commercialization Plan for APHEXDA (Motixafortide) in Stem Cell Mobilization
7:00am
424B5
o5duq7ikn
20 Sep 22
Prospectus supplement for primary offering
4:30pm
6-K
EX-99
9aubu7pb4 2bq0avx5
15 Sep 22
Current report (foreign)
8:39am
6-K
EX-99
v4blv re9t6s69
16 Aug 22
BioLineRx Reports Second Quarter 2022 Financial Results
7:19am
6-K
EX-99
dqwt66p
27 May 22
2022 Annual General Meeting of Shareholders
4:30pm
6-K
EX-99
lkaw46y6j r25zc
11 May 22
BioLineRx Reports First Quarter 2022 Financial Results
7:14am
6-K
EX-99
eeo 442y7lf
24 Jan 22
BioLineRx Announces Completion of Enrollment of Phase 1/2a
7:11am
6-K
EX-99
juim3xwwx5apiqu2s
18 Nov 21
BioLineRx Reports Third Quarter 2021 Financial Results
7:16am